Full Press Release Details
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034)
PRIMA BIOMED TO PRESENT AT THE 15TH ANNUAL BIO CEO & INVESTOR CONFERENCE
Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) has announced today that Matthew Lehman, its Chief Executive Officer, will present at the 15th Annual BIO CEO & Investor Conference on Tuesday,
12 February 2013 at 11:30 am Eastern US Time in New York, NY. Mr. Lehman will provide an overview of the Company and its corporate activities.
The presentation will be a live audio webcast and may be accessed by visiting Prima BioMed s website at http://www.primabiomed.com.au/investor/presentations.php. A replay of the webcast will
be available for 90 days following the presentation.
Prima BioMed is a globally active biotechnology company. As a leader in
personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and to maximize value to shareholders. Prima s lead product is
CVac , an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.
further information please contact:
Ms. Jessica Brown, Prima BioMed Ltd.
Australia Investor/Media:
Mr. James Moses, Mandate Corporate
+61 (0) 420 991 574;
Europe Investor/Media:
Mr. Axel M hlhaus, edicto GmbH
+49 (0) 69 905505-52; amuehlhaus@edicto.de
BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284